NovoCure Ltd (NVCR) Financial Statements
Industry: Surgical & Medical Instruments & Apparatus
In fiscal 2025, NovoCure reported revenue of $655.4M, up 8.3% from $605.2M the year before. Net income was -$136.2M (a -20.8% net margin), or -$1.22 per diluted share. Gross margin was 74.5% and operating margin was -23.5%. Operating activities generated -$49.0M of cash, leaving -$75.7M of free cash flow. At fiscal year end, NovoCure held $804.3M in total assets against $463.9M in total liabilities, including $93.5M of cash and equivalents.
Open the full interactive NovoCure financials → Quarterly statements, key ratios, valuation history and price charts.
NovoCure Key Stats
| Share Price | $14.30 |
|---|---|
| Market Cap | $1.66B |
| Revenue YoY Growth | +8.3% |
| 52-Week Range | $10.03 – $19.99 |
| Shares Outstanding | 116.0 million (basic, 2026 Q2) |
NovoCure Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $494.4M | $535.0M | $537.8M | $509.3M | $605.2M | $655.4M |
| Gross Profit | $387.9M | $420.2M | $423.0M | $381.1M | $468.0M | $488.5M |
| Operating Income | $30.4M | -$44.3M | -$89.5M | -$232.9M | -$170.5M | -$153.8M |
| Pre-Tax Income | $18.1M | -$52.1M | -$81.8M | -$191.7M | -$131.2M | -$136.2M |
| Income Tax | -$1.7M | $6.3M | $10.7M | $15.3M | $37.5M | -$23,000 |
| Net Income | $19.8M | -$58.4M | -$92.5M | -$207.0M | -$168.6M | -$136.2M |
| Diluted EPS | $0.18 | -$0.56 | -$0.88 | -$1.95 | -$1.56 | -$1.22 |
NovoCure Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $167.2M | $174.3M | $174.1M | $183.6M |
| Net Income | -$37.3M | -$24.5M | -$71.1M | -$15.7M |
| Diluted EPS | -$0.33 | -$0.22 | -$0.62 | -$0.13 |
NovoCure Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $234.7M | $208.8M | $115.3M | $240.8M | $163.8M | $93.5M |
| Current Assets | $999.4M | $1.07B | $1.11B | $1.03B | $1.11B | $646.7M |
| Total Assets | $1.05B | $1.14B | $1.19B | $1.15B | $1.24B | $804.3M |
| Current Liabilities | $113.6M | $142.6M | $158.8M | $179.1M | $756.4M | $223.2M |
| Total Long-Term Debt | $429.9M | $562.2M | $565.5M | $568.8M | $97.3M | $195.0M |
| Total Liabilities | $575.5M | $729.0M | $750.5M | $783.6M | $880.6M | $463.9M |
| Shareholders' Equity | $476.5M | $410.5M | $441.2M | $362.5M | $360.2M | $340.5M |
NovoCure Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | $99.1M | $82.8M | $30.8M | -$73.3M | -$26.4M | -$49.0M |
| Cash From Investing | -$472.8M | -$144.8M | -$140.0M | $184.1M | -$140.2M | $437.3M |
| Cash From Financing | $440.2M | $25.7M | $15.5M | $15.8M | $90.3M | -$451.3M |
| Free Cash Flow | $84.2M | $58.6M | $9.4M | -$100.4M | -$69.2M | -$75.7M |
Figures from NovoCure's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full NovoCure financials page for every line item.
NovoCure Company Profile
| Ticker | NVCR |
|---|---|
| Exchange | Nasdaq |
| Industry | Surgical & Medical Instruments & Apparatus |
| Headquarters | St. Helier |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001645113 |
Frequently Asked Questions
What was NovoCure's revenue in fiscal 2025?
NovoCure (NVCR) reported revenue of $655.4M for fiscal 2025.
What is NovoCure's annual revenue history?
NovoCure's annual revenue by fiscal year: 2020: $494.4M; 2021: $535.0M; 2022: $537.8M; 2023: $509.3M; 2024: $605.2M; 2025: $655.4M.
What was NovoCure's net income in fiscal 2025?
NovoCure reported net income of -$136.2M for fiscal 2025.
What was NovoCure's earnings per share (EPS) in fiscal 2025?
NovoCure's diluted EPS was -$1.22 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did NovoCure generate in fiscal 2025?
NovoCure generated -$75.7M of free cash flow in fiscal 2025.
What was NovoCure's revenue last quarter?
In its most recent reported quarter (2026 Q2), NovoCure reported revenue of $183.6M.
How much debt does NovoCure have?
NovoCure reported $195.0M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of NovoCure are outstanding?
NovoCure reported a weighted average of 116.0 million basic shares outstanding in 2026 Q2.
What is NovoCure's market cap?
Based on its latest closing price, NovoCure (NVCR) has a market capitalization of about $1.66B.
When does NovoCure's fiscal year end?
NovoCure's fiscal year end, as registered with the SEC, is December 31.
Where is NovoCure headquartered?
NovoCure lists its business address in St. Helier in its SEC filings.
NovoCure Competitors & Similar Companies
See all 109 Surgical & Medical Instruments & Apparatus companies →